FNY Investment Advisers, LLC
Position in ESPR — Esperion Therapeutics, Inc.
CIK 1742998
NEW YORK, NY
Position in ESPR
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$347,600
+$347,600 QoQ
Shares Held
110,000
Ownership
0.043%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#8
of 29 holders
Holding Since
Mar 2023
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ESPR
reported options exposure · as of Mar 31, 2023CallValue
$15
CallShares
10
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $2,159,974 across 8 Drug Manufacturers - Specialty & Generic names. ESPR ranks #2 (16.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LQDA |
Liquidia Corp
|
17,500 | $1,395,275 | |
| 2 | ESPR |
Esperion Therapeutics, Inc.
This page
|
110,000 | $347,600 | |
| 3 | HIMS |
Hims & Hers Health, Inc.
|
10,010 | $347,046 | |
| 4 | GLAS |
Glass House Brands Inc.
|
5,000 | $65,000 | |
| 5 | CRON |
Cronos Group Inc.
|
1,000 | $2,780 | |
| 6 | TLRY |
Tilray Brands, Inc.
|
300 | $1,347 | |
| 7 | BHC |
Bausch Health Companies Inc.
|
140 | $690 | |
| 8 | AYTU |
Aytu Biopharma, Inc
|
110 | $236 |
All Filings in ESPR
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $347,600 | 110,000 | Shares | Sole | 2026-07-08 | |
| 2023-03-31 | $15 | 10 | Call | Sole | 2023-04-12 | |
| No filing history on record for this holder in this stock. | ||||||